Welcome to our dedicated page for Nice SEC filings (Ticker: NCSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NICE SYSTEMS LTD ORD (NCSYF) provides access to regulatory documents associated with NICE Ltd., a foreign private issuer that reports under the Securities Exchange Act of 1934. NICE Ltd. files annual reports on Form 20-F and furnishes event-driven information on Form 6-K, making these filings central sources of information for investors analyzing NCSYF.
Form 6-K current reports for NICE Ltd. include a range of exhibits, such as press releases on cloud revenue growth and revenue guidance, announcements of financial capital markets day webcasts, and GAAP financial statements that are incorporated by reference into numerous Form S-8 registration statements. Other 6-Ks furnish information on ESG performance, AI customer experience capabilities, contact center-related market assessments, partnerships, executive appointments and brand ambassador arrangements.
Certain Form 6-K filings also describe the results of the company’s annual general meeting of shareholders, including approval of proposals detailed in proxy statements previously submitted to the SEC. These documents, together with the Form 20-F annual reports, form the core regulatory record for NICE Ltd. and are key for understanding governance, financial reporting and corporate actions relevant to NCSYF.
On this filings page, users can review NICE Ltd.’s 6-K submissions and related materials as they appear in the SEC’s EDGAR system. AI-powered tools on the platform can help summarize lengthy filings, highlight key points in 10-K or 20-F style annual reports, clarify quarterly information contained in 6-Ks, and surface details from insider-related and equity compensation disclosures linked to Form S-8 references. This allows investors to navigate NICE Ltd.’s regulatory history more efficiently while focusing on the specific filing types and topics most relevant to their analysis of NCSYF.
NICE Ltd. reported that VP, General Counsel & Corporate Secretary Levy Meir Alon received a grant of stock options. The award covers 5,000 options for Ordinary Shares with an exercise price of $0.3211 per share and an expiration date of April 1, 2032.
The options vest in substantially equal installments on April 1, 2027, April 1, 2028, April 1, 2029, and April 1, 2030. Following this grant, Alon holds a total of 5,000 options directly.
NICE Ltd. reported that VP of Corporate Finance Dayan Udi Yehuda received a grant of 5,000 stock options linked to 5,000 Ordinary Shares. The options have an exercise price of 0.3211 per share and expire on April 1, 2032. According to the disclosure, the stock option will vest in substantially equal installments on April 1, 2027, April 1, 2028, April 1, 2029, and April 1, 2030. This is a compensation-related award, not an open-market purchase or sale, and after the grant he holds 5,000 options directly.
NICE Ltd. director Zehava Simon filed an initial statement of beneficial ownership, outlining existing holdings in options and ordinary shares. The filing lists multiple option grants over ordinary shares with exercise prices ranging from 0.2657 to 232.2005 and expiration dates between 2026 and 2031. Footnotes state that some stock options are already fully vested and exercisable, while others vest over time, including one grant that vests in three substantially equal installments on March 30, 2026, June 30, 2026 and September 30, 2026. The filing also reports direct ownership of 3,439 ordinary shares, giving investors a clear view of the director’s current equity stake rather than any new transaction.
NICE Ltd. director Dvir Yocheved has reported current equity holdings in a Form 3 insider filing. The disclosure lists multiple stock option awards over NICE ordinary shares with exercise prices ranging from 0.2929 to 232.2005 and expiration dates between 2026 and 2031. The filing also shows direct ownership of 395 NICE ordinary shares. Footnotes explain that some options are already fully vested and exercisable, while others will vest in installments through specific dates in 2026.
NICE Ltd. executive Udi Yehuda Dayan, VP of Corporate Finance, filed an initial insider report listing existing stock option holdings in the company’s Ordinary Shares. The filing shows options over 750 Ordinary Shares at an exercise price of 0.3060 expiring on March 14, 2028, and 3,000 Ordinary Shares at an exercise price of 0.3134 expiring on December 23, 2031, among other grants. Footnotes explain that some options are already vested and exercisable, while others will vest in scheduled installments through 2030. No new purchases or sales are reported; this Form 3 simply establishes Dayan’s existing option positions.
NICE Ltd. executive vice president of human resources Neder Shiri reported existing holdings of stock options on the company’s Ordinary Shares. The awards have exercise prices ranging from 0.2706 to 0.3228 and individual grants covering 1,200 to 12,500 underlying shares, with expirations between March 3, 2027 and February 18, 2033.
Footnotes explain that several options are already vested and exercisable, while others vest over future dates in 2027, 2028 and 2029. One performance-based grant is eligible to vest over a three-year performance period ending February 18, 2029, depending on specified stock price thresholds.
NICE Ltd. Chief Executive Officer Russell Scott Edward reported his initial ownership in the company. He directly holds 65,989 Ordinary Shares and has Performance Share Units linked to 27,500 underlying Ordinary Shares.
Footnotes add that his equity awards include 33,000 restricted stock units and 16,500 performance stock units, each representing a contingent right to receive one Ordinary Share, vesting under their award terms. Certain performance share units are eligible to vest over a three-year period ending January 1, 2028 based on specified stock price performance thresholds.
NICE Ltd. director Ben-Shaoul Rimon filed an initial Form 3 reporting his equity holdings in the company. He directly owns 995 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with varying exercise prices and expiration dates.
These options include grants exercisable for 3,980 shares at an exercise price of 151.6300 per share expiring on April 30, 2026, and others such as 2,785 shares at 224.1800 per share expiring on September 10, 2026. Footnotes state that some options are fully vested and currently exercisable, while others vest in installments through September 30, 2026.
NICE Ltd. director Leo Apotheker filed an initial ownership report showing multiple stock option grants over Ordinary Shares. The options cover various underlying share amounts with exercise prices such as 224.1800 and 144.9030 and expiration dates from 2026 through 2031, with some already fully vested and others vesting through September 30, 2026.
NICE Ltd. director Joseph Lamar Cowan filed an initial Form 3 detailing his equity stake in the company. He reports direct ownership of 4,769 Ordinary Shares, which includes 746 restricted stock units that vest under the terms of their awards, each representing one Ordinary Share.
Cowan also reports indirect ownership of 11,183 Ordinary Shares held by a corporation, and several option grants over Ordinary Shares. These stock options carry exercise prices ranging from $144.9030 to $232.2005 per share and expire between April 2026 and September 2031, with some fully vested and others scheduled to vest in installments during 2026.